Long-Term Follow-Up of Local Relaxing Vitrectomy for Stage 4 Retinopathy of Prematurity

2010 ◽  
Author(s):  
Yan-Rong Jiang ◽  
Peng Zhou
Keyword(s):  
Retinopathy Of Prematurity ◽  
Stage 4 ◽  
Long Term Follow Up

Long-term follow-up of differentiated thyroid carcinoma in children and adolescents

2020 ◽  
Vol 33 (11) ◽  
pp. 1431-1441
Author(s):  
Montserrat Negre Busó ◽  
Amparo García Burillo ◽  
Marc Simó Perdigó ◽  
Pere Galofré Mora ◽  
Maria Boronat de Ferrater ◽  
...  
Keyword(s):  
Complete Remission ◽  
Thyroid Carcinoma ◽  
Children And Adolescents ◽  
Differentiated Thyroid Carcinoma ◽  
Radioiodine Treatment ◽  
Persistent Disease ◽  
Stage 4 ◽  
Long Term Follow Up

AbstractObjectivesThe aims were to analyze the clinical features, response to treatment, prognostic factors and long-term follow-up of children and adolescents with differentiated thyroid carcinoma (DTC).MethodsEighty patients with DTC were studied retrospectively. All underwent total or near-total thyroidectomy, and in 75 cases, ablative iodine therapy was recommended. Patients were assessed periodically by tests for serum thyroglobulin levels and whole-body iodine scans. Age, gender, initial clinical presentation, histology, tumor stage, postoperative complications, radioiodine treatment protocol, treatment response, thyroglobulin (Tg), recurrence and long-term disease progression were evaluated.ResultsSeventy patients completed >2 years of follow-up (23 males, 47 females; median age: 14 years; range: 3–18 years). Sixty-two patients showed papillary DTC and eight, follicular DTC. Sixty-five percent presented nodal metastasis and 16%, pulmonary metastasis at diagnosis. Six months after first radioiodine treatment, 36.2% of patients were free of disease. Seven recurrences were documented. At the end of follow-up, overall survival was 100%, and 87.2% of patients were in complete remission. Nine patients had persistent disease. We found a significant association between stage 4 and persistent disease. Hundred percent of patients with negative Tg values at 6 months posttreatment were documented free of disease at the end of the follow-up. The analysis of disease-free survival based on radioiodine treatment protocols used showed no statistically significant differences.ConclusionsDTC in children and adolescents is frequently associated with presence of advanced disease at diagnosis. Despite this, complete remission was documented after treatment in most cases, with a good prognosis in the long-term follow-up. Negative posttreatment thyroglobulin and stage 4 at diagnosis were significant prognostic variables.

Long-term Follow-up of Visual Acuity in Eyes With Stage 5 Retinopathy of Prematurity After Closed Vitrectomy

1995 ◽  
Vol 120 (3) ◽  
pp. 308-316 ◽  
Author(s):  
YUKI FUCHINO ◽  
HIDEYUKI HAYASHI ◽  
TOSHIHIRO KONO ◽  
KENJI OHSHIMA
Keyword(s):  
Visual Acuity ◽  
Retinopathy Of Prematurity ◽  
Long Term Follow Up

scholarly journals A Long-term Follow-up Study on the Visual Functions in Cicatricial Stage of Retinopathy of Prematurity.

1990 ◽  
Vol 18 ◽  
pp. 217-226
Author(s):  
Hiroko SUZUKI ◽  
Nagisa AKAIKE ◽  
Kayoko HARASAWA ◽  
Yoshihiro WAKABAYASHI ◽  
Tadao AGAWA
Keyword(s):  
Retinopathy Of Prematurity ◽  
Visual Functions ◽  
Follow Up Study ◽  
Long Term Follow Up

scholarly journals PO-0388 Long Term Follow Up Of A Cohort Of Preterm Infants Diagnosed Of Retinopathy Of Prematurity: Abstract PO-0388 Table 1

2014 ◽  
Vol 99 (Suppl 2) ◽  
pp. A372.2-A372
Author(s):  
C Balcells ◽  
T Agut ◽  
C Moreno ◽  
A Serra ◽  
M Morales ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Retinopathy Of Prematurity ◽  
Long Term Follow Up

scholarly journals Morbidity and functional mid-term outcomes using the Prolift pelvic floor repair systems

2014 ◽  
Vol 8 (9-10) ◽  
pp. 605 ◽  
Author(s):  
Sébastien Kozal ◽  
Thomas Ripert ◽  
Younes Bayoud ◽  
Johan Menard ◽  
Ioannis Nicolacopoulos ◽  
...  
Keyword(s):  
Functional Outcomes ◽  
De Novo ◽  
Genital Prolapse ◽  
Market Withdrawal ◽  
Prolapse Recurrence ◽  
Related Risk ◽  
Stage 4 ◽  
Long Term Follow Up

Introduction: We assess midterm morbidity and functional outcomes using the Prolift (Gynecare/Ethicon, Somerville, NJ) system and identify potential related risk factors. The Prolift mesh system to treat genital prolapse was introduced in 2005. It was withdrawn from the market in early 2013 after rising doubts about safety.Methods: Over a 7-year period, we retrospectively analyzed a cohort of 112 consecutive patients who underwent the Prolift procedure since 2006. Intraoperative and postoperative complications, anatomical and functional outcomes were recorded.Results: The median follow-up was 49.5 months (range: 16-85). The mean age was 64.7 ± 10.9 years (range: 40-86). Of the 112 patients, 74 patients had stage 3 (66.1%) and 8 patients had stage 4 (7.14%) vaginal prolapse. Prolift surgery was performed for prolapse recurrence for 26 patients (23.2%). Total mesh was used in 32 patients (29%), an isolated anterior mesh in 57 patients (51%) and an isolated posterior mesh in 23 patients (21%). Concomitant surgical procedures were performed for 44 patients (39.3%). Overall, 72% (18/25) of the complications were managed medically. We reported a failure rate of 8% (n = 9) occurring after a median follow-up of 9.5 months (range: 1-45). Among the 64 patients who had preoperative sexual activity (57.1%), de novo dyspareunia occurred in 9 patients (16.07%). We extracted predictive factors concerning failure, complications and sexuality.Conclusion: Despite its market withdrawal, the Prolift system was associated with good midterm anatomic outcomes and few severe complications. Long-term follow-up data are still lacking, but surgeons and patients may be reassured.

Long-Term Follow-up in Patients With Retinopathy of Prematurity

2011 ◽  
Vol 48 (6) ◽  
pp. 328-332
Author(s):  
Michael F. Chiang ◽  
Steven J. Lichtenstein ◽  
James D. Reynolds
Keyword(s):  
Retinopathy Of Prematurity ◽  
Long Term Follow Up

scholarly journals Dynamic Analysis of Ocular Fundus Changes after Different Doses of Bevacizumab in the Treatment of Retinopathy of Prematurity in Threshold Period

2021 ◽  
Author(s):  
Feng Chen ◽  
Ying Yu ◽  
Jianxun Wang ◽  
Tian Liu ◽  
Daoman Xiang
Keyword(s):  
Retinopathy Of Prematurity ◽  
Fundus Examination ◽  
Time Points ◽  
Bevacizumab Treatment ◽  
Significant Difference ◽  
Long Term Follow Up ◽  
Consecutive Time ◽  
Different Doses

Abstract Purpose: To analyze the efficacy of three different doses of bevacizumab treatment on Threshold retinopathy of prematurity during different periods . Methods: 36 cases (72 eyes) of infants with threshold ROP were analyzed, whom were treated with intravitreal injection of 1.25mg, 0.75mg or 0.5mg bevacizumab respectively from October 1st, 2016 to September 30th, 2017. After treatment, fundus examination results during five time points were recorded and classified into four grades according to the efficacy. Results: There were significant differences in the changes of fundus among the 3 groups on the 4th day and the 2nd week after treatment （P<0.001）. In the 1.25mg group, there was a significant difference in the changes of fundus on the 4th day after treatment VS. the 2nd week after treatment (P<0.001). In the 0.5mg and 0.75mg group respectively, the changes of fundus were significantly different between each consecutive time points of the 4th day, 2nd week, 4th week and 2nd month after treatment (P<0.001,P<0.001,P=0.01; P<0.001,P=0.01,P=0.032). The proportion of normal retinal vessels of the three groups is 41.67% - 66. 67% in the 3rd month after treatment.Conclusion: Among the three doses of bevacizumab treatment, the efficacy of 1.25mg group is the best on the 4th day and the 2nd week after treatment, and there was no difference after 4 weeks. The efficacy of 0.5mg and 0.75mg group changed significantly from the 4th day to the 2nd month after treatment. Long-term follow-up of fundus changes was still needed to avoid recurrence of ROP whatever the dose of bevacizumab was uesed.

scholarly journals Dynamic Analysis of Ocular Fundus Changes After Different Doses of Bevacizumab in the Treatment of Retinopathy of Prematurity in Threshold Period

2021 ◽  
Author(s):  
Feng Chen ◽  
Daoman Xiang ◽  
Ying Yu ◽  
Jianxun Wang ◽  
Tian Liu
Keyword(s):  
Retinopathy Of Prematurity ◽  
Statistical Significance ◽  
Time Points ◽  
Bevacizumab Treatment ◽  
Significant Difference ◽  
Long Term Follow Up ◽  
Consecutive Time ◽  
Different Doses

Abstract Purpose: To analyze the efficacy of three different doses of bevacizumab treatment on Threshold retinopathy of prematurity during different periods . Methods: 36 cases (72 eyes) of infants with threshold ROP were analyzed, whom were treated with intravitreal injection of 1.25 mg, 0.75 mg or 0.5 mg bevacizumab respectively from October 1st, 2016 to September 30th, 2017. After treatment, fundus examination results during five time points were recorded and classified into four grades according to the efficacy. Results: There were significant differences in the changes of fundus among the 3 groups from the 4th day to the 4th week after treatment （P<0.01）. In the 1.25 mg group, there was a significant difference in the changes of fundus on the 4th day after treatment VS. the 2nd week after treatment (P<0.001). In the 0.75 mg and 0.5 mg group respectively, the changes of fundus were significantly different between each consecutive time points of the 4th day, 2nd week, 4th week and 2nd month after treatment (P<0.001,P=0.001,P=0.002; P<0.001,P=0.001,P=0.003). The proportion of normal retinal vessels respectively in 1.25 mg , 0.75 mg and 0.5 mg group is 66.67%、43.48% and 50% in the 3rd month after treatment.Conclusion: Retinal complete vascularization was slightly better in 1.25 mg group, but failed to reach a statistical significance. Based on results, the lowest dose 0.5 mg may be preferred since our final results were similar (p>0.05). Long-term follow-up of fundus changes was still needed to avoid recurrence of ROP whatever the dose of bevacizumab was uesed.

Sign in / Sign up

Export Citation Format

Share Document